Autoantibody profiles in systemic sclerosis: Predictive value for clinical evaluation and prognosis
- 24 January 2010
- journal article
- review article
- Published by Wiley in The Journal of Dermatology
- Vol. 37 (1), 42-53
- https://doi.org/10.1111/j.1346-8138.2009.00762.x
Abstract
Systemic sclerosis (SSc) is thought to be an autoimmune disease, as autoantibodies against a variety of extractable nuclear antigens can be detected in patient sera. Subgrouping patients based on the type of autoantibodies present can be useful in diagnosis and management. Anti-centromere antibodies (ACA) and anti-topoisomerase I antibodies (anti-topo I) are the classic autoantibodies associated with SSc. ACA are associated with limited cutaneous involvement and isolated pulmonary hypertension, whereas anti-topo I are associated with diffuse skin involvement and pulmonary fibrosis. ACA are predictors for a favorable prognosis, while anti-topo I are correlated with a poor prognosis and SSc-related mortality. Additionally, anti-RNA polymerase antibodies (anti-RNAP) are associated with diffuse cutaneous disease and renal involvement. Anti-nucleolar antibodies define multiple subgroups of patients with SSc. Of these, anti-Th/To antibodies (anti-Th/To) and anti-PM-Scl antibodies (anti-PM-Scl) are associated with limited cutaneous SSc (lSSc), whereas anti-U3RNP antibodies (anti-U3RNP) are associated with diffuse cutaneous SSc (dSSc). In addition, anti-Th/To and anti-U3RNP can be predictors for a less favorable prognosis with a higher frequency of organ involvement, such as pulmonary fibrosis, pulmonary hypertension and renal crisis. Other autoantibodies are less frequently reported: anti-Ku antibodies, anti-U1RNP antibodies, anti-human upstream-binding factor, and anti-U11/U12 antibodies. These antibodies are generally less specific to SSc, but also define clinically distinct patient subsets. Thus, characterization of autoantibodies in SSc together with knowledge of disease characteristics intrinsic to distinct patient populations is helpful for assessing the clinical presentation and prognosis of this disease, and for monitoring patients with SSc.Keywords
This publication has 93 references indexed in Scilit:
- Anti–U11/U12 RNP antibodies in systemic sclerosis: A new serologic marker associated with pulmonary fibrosisArthritis Care & Research, 2009
- Lack of evidence of stimulatory autoantibodies to platelet‐derived growth factor receptor in patients with systemic sclerosisArthritis & Rheumatism, 2009
- The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosisBritish Journal of Dermatology, 2008
- Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group databaseAnnals Of The Rheumatic Diseases, 2007
- DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti–topoisomerase I autoantibodies from systemic sclerosis patientsArthritis & Rheumatism, 2006
- Diversity and plasticity of the anti-DNA topoisomerase I autoantibody response in sclerodermaArthritis & Rheumatism, 2000
- Longitudinal Study of Anticentromere and Antitopoisomerase-I IsotypesClinical Immunology and Immunopathology, 1995
- Autoantibodies to RNA polymerase II are common in systemic lupus erythematosus and overlap syndrome. Specific recognition of the phosphorylated (IIO) form by a subset of human sera.JCI Insight, 1994
- Human autoantibody to RNA polymerase I transcription factor hUBF. Molecular identity of nucleolus organizer region autoantigen NOR-90 and ribosomal RNA transcription upstream binding factor.The Journal of Experimental Medicine, 1991
- Anticentromere antibodies in primary biliary cirrhosisArthritis & Rheumatism, 1983